Literature DB >> 16679518

Expression of foreign protein epitopes at the surface of recombinant yellow fever 17D viruses based on three-dimensional modeling of its envelope protein.

Myrna C Bonaldo1, Richard C Garratt, Marcos S Freire, Ricardo Galler.   

Abstract

The yellow fever (YF) 17D vaccine is a live attenuated virus, and its genetic manipulation constitutes a new platform for vaccine development. In this article, we review one of the possible approaches to enable this development, which is the insertion of foreign protein epitopes into different locations of the genome. We describe the three-dimensional (3D) modeling of the YF 17D virus E protein structure based on tick-borne encephalitis (TBE) and the identification of a potential insertion site located at the YF 17D fg loop. Further 3D analysis revealed that it is possible to accommodate inserts of different sizes and amino acid composition in the flavivirus E protein fg loop. We demonstrate that seven YF 17D viruses bearing foreign epitopes that vary in sequence and length show differential growth characteristics in cell culture. The testing of recombinant viruses for mouse neurovirulence suggests that insertions at the 17D E protein fg loop do not compromise the attenuated phenotype of YF 17D virus, further confirming the potential use of this site for the development of new live attenuated 17D virus-based vaccines.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16679518     DOI: 10.1385/CBB:44:3:313

Source DB:  PubMed          Journal:  Cell Biochem Biophys        ISSN: 1085-9195            Impact factor:   2.194


  7 in total

Review 1.  The yellow fever 17D virus as a platform for new live attenuated vaccines.

Authors:  Myrna C Bonaldo; Patrícia C Sequeira; Ricardo Galler
Journal:  Hum Vaccin Immunother       Date:  2014-02-19       Impact factor: 3.452

2.  The C Terminus of the Core β-Ladder Domain in Japanese Encephalitis Virus Nonstructural Protein 1 Is Flexible for Accommodation of Heterologous Epitope Fusion.

Authors:  Li-Chen Yen; Jia-Teh Liao; Hwei-Jen Lee; Wei-Yuan Chou; Chun-Wei Chen; Yi-Ling Lin; Ching-Len Liao
Journal:  J Virol       Date:  2015-11-11       Impact factor: 5.103

3.  Biological and immunological characterization of recombinant Yellow Fever 17D viruses expressing a Trypanosoma cruzi Amastigote Surface Protein-2 CD8+ T cell epitope at two distinct regions of the genome.

Authors:  Raquel T Nogueira; Alanderson R Nogueira; Mirian C S Pereira; Maurício M Rodrigues; Ricardo Galler; Myrna C Bonaldo
Journal:  Virol J       Date:  2011-03-18       Impact factor: 4.099

4.  Yellow fever virus envelope protein expressed in insect cells is capable of syncytium formation in lepidopteran cells and could be used for immunodetection of YFV in human sera.

Authors:  Maria C E S Barros; Tatiane G C M Galasso; Antônio J M Chaib; Nicolas Degallier; Tatsuya Nagata; Bergmann M Ribeiro
Journal:  Virol J       Date:  2011-05-27       Impact factor: 4.099

5.  Rational design of novel fusion rabies glycoproteins displaying a major antigenic site of foot-and-mouth disease virus for vaccine applications.

Authors:  Ernesto Garay; Diego Fontana; Lautaro Leschiutta; Ricardo Kratje; Claudio Prieto
Journal:  Appl Microbiol Biotechnol       Date:  2021-12-31       Impact factor: 4.813

6.  A Yellow Fever 17D Virus Replicon-Based Vaccine Platform for Emerging Coronaviruses.

Authors:  Nadia Oreshkova; Sebenzile K Myeni; Niraj Mishra; Irina C Albulescu; Tim J Dalebout; Eric J Snijder; Peter J Bredenbeek; Kai Dallmeier; Marjolein Kikkert
Journal:  Vaccines (Basel)       Date:  2021-12-16

7.  Immunogenicity of seven new recombinant yellow fever viruses 17D expressing fragments of SIVmac239 Gag, Nef, and Vif in Indian rhesus macaques.

Authors:  Mauricio A Martins; Myrna C Bonaldo; Richard A Rudersdorf; Shari M Piaskowski; Eva G Rakasz; Kim L Weisgrau; Jessica R Furlott; Christopher M Eernisse; Marlon G Veloso de Santana; Bertha Hidalgo; Thomas C Friedrich; Maria J Chiuchiolo; Christopher L Parks; Nancy A Wilson; David B Allison; Ricardo Galler; David I Watkins
Journal:  PLoS One       Date:  2013-01-15       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.